Foresite Capital Research
Investment Thesis
Foresite Capital is a data-science-driven healthcare and life sciences investment firm founded in 2011 by Jim Tananbaum, MD. The firm's stated mission is to invest in companies that leverage biology and big data to transform healthcare, marrying technology and biotechnology to personalize medicine and accelerate innovation. Tananbaum has described the firm's core belief as: "The healthcare sector is experiencing unprecedented innovation driven by understanding vast amounts of biologic and genetic information, a change we believe is leading to some of the most impactful medical solutions in decades." Foresite pairs its capital with a deep internal bench of MDs, PhDs, and data scientists who evaluate science and clinical risk alongside traditional financial diligence.
Sector Focus
Foresite invests exclusively within healthcare and life sciences, spanning:
- Biopharmaceuticals and novel therapeutics
- Genomics and genetic diseases
- Diagnostics and life-science tools
- Healthcare technology and services
- AI-enabled drug discovery
The firm explicitly targets companies operating at the intersection of technology and biotechnology, with a particular emphasis on data-rich approaches to drug discovery and personalized medicine.
Stage Focus
Foresite describes itself as a "full lifecycle" investor, funding companies "from incubation to IPO and beyond." In practice this means the firm participates from company creation and seed-stage incubation (e.g., co-founding Xaira Therapeutics) through Series A-D and growth equity, and continues to hold positions into and after public listings. Third-party trackers characterize Foresite's most common entry point as Series B, though the firm is active at Series A through growth stage.
Check Size
Check sizes vary widely with stage and conviction. Around its Fund VI close, the firm indicated it planned to write checks "from a couple of million up to $75 million" across roughly 20 portfolio companies. Third-party estimates for later-stage and growth rounds put typical checks in the $50M-$120M range, consistent with Foresite's role as a large-check co-lead in growth financings.
Lead Tendency
Foresite both leads and co-leads. It has been sole/lead investor in earlier-stage and incubated situations (Xaira Therapeutics), and has co-led larger growth rounds alongside other specialist healthcare investors (Slate Medicines with RA Capital and Forbion; Pinnacle Medicines with LAV; Thyme Care with Town Hall Ventures).
Recent Activity
Fund VI, a $900M vehicle, closed in June 2024 and remains in active deployment. Recent financings include a co-lead of Slate Medicines' $130M Series A (February 2026) to advance anti-PACAP migraine therapies, a co-lead of Pinnacle Medicines' oversubscribed $89M Series B (March 2026) for oral peptide therapeutics, and participation as a new investor in Stepful's $55M Series C (June 2026) for AI-powered healthcare workforce training. In April 2024, Foresite Labs (the firm's incubation affiliate) co-founded and backed the $1B launch of Xaira Therapeutics, an AI-driven drug discovery company, alongside ARCH Venture Partners and Nobel laureate David Baker. Foresite was named to TIME's list of America's Top Venture Capital Firms for 2025.
Portfolio Highlights
Foresite's active and historical portfolio spans more than 200 companies. Notable exits and alumni include 10x Genomics (IPO), GRAIL, Blueprint Medicines (acquired by Sanofi), Novavax, Acceleron Pharma (acquired by Merck), and Natera. Current holdings span biopharma (Denali Therapeutics, Cytokinetics, Celldex Therapeutics, Centessa Pharmaceuticals, Corvus Pharmaceuticals, Lyell Immunopharma, Maze Therapeutics, Cerevance), life-science tools and diagnostics (Mammoth Biosciences, DNAnexus, Delfi Diagnostics, Element Biosciences, Bit Bio, CG Oncology), and healthcare tech/services (Hinge Health, Color Health, HealthVerity, Thyme Care, insitro, Xaira Therapeutics, Stepful).
Team
Foresite is led by Founder & CEO Jim Tananbaum, MD (Midas List honoree), supported by a group of Managing Directors and Partners with deep scientific and financial backgrounds:
- Jim Tananbaum, MD - Founder & CEO
- Dorothy Margolskee, MD - Managing Director
- Michael Rome, PhD - Managing Director
- Hadi Tabbaa - Managing Director
- Stephen C. Peterson, CFA - Managing Director
- Richard Lau, CFA - Partner
- Hyung Chun, MD - Partner
- Shannon Bergstedt - Partner
- Vikram Bajaj, PhD - Advisor
- Deepak Atri, MD - Principal
- Vishal Deshmukh, PhD - Principal
- Collin Yang-Wong - Principal
- Uplaksh Kumar - Venture Partner
The firm employs 50+ people including a large internal team of MD/PhD scientists and data scientists who work alongside the investment team on diligence and portfolio support.
Decision Process
Investment decisions run through a partnership of Managing Directors and Partners rather than a single decision-maker, reflecting the firm's emphasis on "deep collaboration" between clinical/scientific experts and investment professionals.
Founder Preferences
Foresite gravitates toward founding teams with strong scientific or clinical credentials tackling areas of unmet medical need, particularly where large biological or genetic datasets can be applied to drug discovery, diagnostics, or care delivery. The firm has also directly co-founded and incubated companies (e.g., Xaira Therapeutics) rather than purely investing in existing teams.
Geographic Focus
Foresite is US-focused, with offices in the San Francisco Bay Area (Larkspur, CA), West Hollywood, CA, and New York City, and a portfolio concentrated in US healthcare and life-science hubs.